查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571821

基于人工智慧的临床试验解决方案供应商市场规模、份额和趋势分析报告：按治疗应用、按临床试验阶段、按最终用途、按地区、按细分市场、预测，2024-2030 年

AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report By Therapeutic Application, By Clinical Trial Phase, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 118 Pages | 商品交期: 2-10个工作天内

价格

基于人工智慧的临床试验解决方案供应商市场成长和趋势：

根据 Grand View Research, Inc. 的最新报告，到 2030 年，基于人工智慧的临床试验解决方案供应商的全球市场规模预计将达到 78 亿美元，预测期内复合年增长率为 22.1%。

人工智慧是一种多功能工具，越来越多地用于提高药物研究的运作效率并加速药物发现过程。它也被大量使用以最大限度地降低药物开发过程中的成本。各个学术界和製药公司正在积极采用基于人工智慧的平台和技术。例如，2020 年 1 月，拜耳与一家英国人工智慧主导的药物发现公司建立了伙伴关係，利用其人工智慧药物发现平台进行早期研究计划。此外，公共和私人促进研发的措施以及人工智慧在药物研究领域提供的多样化应用正在推动成长。

从临床试验阶段来看，由于药物发现数量不断增加以及二期临床试验数量众多，二期临床试验将在 2023 年以 45.5% 的份额占据市场主导地位。此外，在此阶段越来越多地采用基于人工智慧的工具来收集资料并透过临床试验即时分析整体预期结果，这也有助于该细分市场的成长。此外，由于在此阶段可以对基于人工智慧的工具进行改进、决策和措施检验，因此该细分市场拥有更高的收益占有率。

基于治疗应用，肿瘤学在 2023 年基于人工智慧的临床试验解决方案供应商市场中占据最高收益占有率。全球癌症盛行率的不断上升以及肿瘤学领域药物研究数量的增加正在促进人工智慧技术的采用。此外，越来越多的参与者正在开发先进的基于肿瘤学的人工智慧工具，并将其用于药物研究，从而推动了这一领域的成长。

2023年，根据最终用途，製药公司在市场上占据最高的收益占有率。大型製药企业越来越多地采用基于人工智慧的技术来识别新药靶点、开发新药和新药测试的整个流程、诊断和生物标誌物的更好开发是该细分市场成长的主要因素之一。此外，这些大型製药企业正在与人工智慧供应商合作，在整个研发和药物发现过程中利用人工智慧技术，这推动了它们的成长。

北美地区主导市场，2023 年收益占有率为 43.4%。这一优势得益于该地区新兴企业数量的不断增加。例如，Bullfrog AI 是一家总部位于美国的新兴企业，它开发了 bfLEAP，这是一个支援精准医疗的专有人工智慧平台。此外，人们对基于人工智慧的技术的认识不断增强，并采用这些技术来提高药物研究成果，正在推动该地区的市场成长。此外，政府支持措施的增加和领先公司的战略倡议正在推动该地区对基于人工智慧的临床试验解决方案的需求。

由于 COVID-19 的爆发，基于人工智慧的技术的采用激增。越来越多地采用技术先进的解决方案来进行药物开发和招募患者的资料分析，这有助于人工智慧解决方案的快速采用。此外，许多药物开发过程在大流行期间被搁置。因此，市场上的许多主要企业已将重点转向利用基于人工智慧的解决方案，从而促进分散的临床临床实验。此外，透过这些解决方案对大量患者资料进行有效分析也支持了市场成长。

基于人工智慧的临床试验解决方案供应商市场报告亮点

  • II 期临床试验部分在 2023 年占据市场主导地位。
  • 由于癌症盛行率上升以及肿瘤学药物研究的增加，肿瘤学领域将在 2023 年占据市场主导地位。
  • 由于大型製药企业越来越多地采用人工智慧技术进行药物开发，製药公司部门在市场上占据了最高的收益占有率。
  • 北美地区占据主导地位，2023 年收益占有率为 43.4%。这是由于多种因素造成的，包括该地区临床试验数量的增加、人工智慧平台和工具的更多采用、基于人工智慧的药物开发新兴企业公司和公司数量的增加以及这是由于人们对基于人工智慧的工具和技术的认识所造成的。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 基于人工智慧的临床试验解决方案供应商市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 的影响
  • 案例研究

第四章 基于人工智慧的临床试验解决方案供应商市场：治疗应用的估算和趋势分析

  • 细分仪表板
  • 2023 年和 2030 年治疗应用趋势和市场占有率分析
  • 按治疗应用分類的基于人工智慧的临床试验解决方案供应商的全球市场前景
  • 肿瘤学
  • CVD
  • 神经系统疾病或病症
  • 代谢性疾病
  • 感染疾病
  • 其他的

第五章 人工智慧的临床试验解决方案供应商市场：临床试验阶段估算及趋势分析

  • 细分仪表板
  • 2023年及2030年临床试验阶段趋势及市场占有率分析
  • 基于人工智慧的临床试验解决方案供应商市场的全球展望（按临床试验阶段）
  • 第一阶段
  • 第二阶段
  • 第三阶段

第六章 基于人工智慧的临床试验解决方案供应商市场：最终用途估计和趋势分析

  • 细分仪表板
  • 2023 年和 2030 年最终用途趋势和市场占有率分析
  • 基于人工智慧的临床试验解决方案供应商的最终用途市场前景
  • 製药公司
  • 学术的
  • 其他的

第七章基于人工智慧的临床试验解决方案供应商市场：区域估计和趋势分析，按治疗应用，按临床试验阶段，按最终用途

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场简介
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 2023年主要企业市场占有率/地位分析
  • 公司简介
    • Unlearn.ai, Inc.
    • Saama
    • Antidote Technologies, Inc.
    • Phesi
    • Deep6.ai
    • Innoplexus
    • Mendel Health Inc.
    • Intelligencia AI
    • Median Technologies
    • SymphonyAI
    • BioAge Labs, Inc.
    • AiCure
    • Consilx
    • DeepLens.AI
    • HaloHealth
    • PHARMASEAL
    • Ardigen
    • Trials.ai
    • Koneksa Health
    • Euretos
    • BioSymetrics, Inc.
    • Verily（Google LLC）
    • Aitia
    • IBM
    • Exscientia
Product Code: GVR-4-68039-456-6

AI-based Clinical Trials Solution Provider Market Growth & Trends:

The global AI-based clinical trials solution provider market size is expected to reach USD 7.8 billion by 2030, registering a CAGR of 22.1% during the forecast period, according to a new report by Grand View Research, Inc.. AI is a versatile tool and is being increasingly utilized to improve the operational efficacy of drug studies and accelerate the drug discovery process. Also, it is highly adopted to minimize the cost of the drug development process. Various academia and pharmaceutical companies are actively adopting AI-based platforms and technologies. For instance, in January 2020, Bayer entered into a partnership with an AI-driven drug discovery company based in the UK to work on early research projects using the AI drug discovery platform. Furthermore, the initiatives by the public and private sectors to boost the R&D coupled with the diverse applications provided by AI in the field of drug studies are impelling the growth.

Based on the phase of the clinical trial, Phase II dominated the market with a share of 45.5% in 2023 owing to the rising number of drug discoveries and a large number of studies active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the clinical trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase.

In 2023, based on therapeutic applications, oncology accounted for the highest revenue share in the AI-based clinical trials solution provider market. The increasing prevalence of cancer across the globe and the rising number of drug studies in the field of oncology is contributing to the adoption of AI enables technologies. Also, an increasing number of players are developing and adopting advanced oncology-based AI tools for drug studies, thereby propelling the segment growth.

In 2023, pharmaceutical companies accounted for the highest revenue share in the market, based on end-use. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify the new drug target and the overall process of drug development and drug trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendor for leveraging the AI technology for R&D and the overall drug discovery process, thereby, impelling the growth.

North America dominated the market and accounted for a revenue share of 43.4% in 2023. This dominance is attributed to the rising number of start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Also, the growing awareness of AI-based technologies and their adoption to enhance the drug studies' outcomes is impelling the market growth in the region. Furthermore, the supportive government initiatives and increasing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region.

The AI-based technologies witnessed a surge in their adoption due to the outbreak of COVID-19. This increasing adoption of technologically advanced solutions for drug development and for the analyses of the recruited patient's data contributed to the upsurge in the adoption of AI-enabled solutions. Moreover, many drug development processes were on hold during the pandemic. Therefore, many key companies in the market shifted their focus on the utilization of AI-based solutions, thereby boosting decentralized drug trials. Furthermore, the effective analysis of a large amount of patient data through these solutions supported the market growth.

AI-based Clinical Trials Solution Provider Market Report Highlights:

  • The phase-II trials segment dominated the market in 2023, owing to the increasing number of active drug studies in this phase
  • The oncology segment dominated the market in 2023, owing to the rising prevalence of cancer and the growing number of drug studies in the oncology field
  • The pharmaceutical companies segment accounted for the highest revenue share in the market owing to the increasing adoption of artificial intelligence technologies for drug development by major pharmaceutical players
  • North America dominated the market and accounted for a revenue share of 43.4% in 2023, owing to various factors including the increasing number of clinical trials in the region, growing adoption of artificial intelligence platforms and tools, rising number of start-ups and companies based on artificial intelligence in drug development and growing awareness regarding AI-based tools and technologies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapeutic applications
    • 1.1.2. Clinical trial phase
    • 1.1.3. End use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapeutic applications outlook
    • 2.2.2. Clinical trial phase outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. AI-Based Clinical Trials Solution Providers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape
    • 3.3.3. COVID-19 Impact
  • 3.4. Case Studies

Chapter 4. AI-Based Clinical Trials Solution Providers Market: Therapeutic Applications Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Therapeutic Applications Movement & Market Share Analysis, 2023 & 2030
  • 4.3. Global AI-Based Clinical Trials Solution Providers Market by Therapeutic Applications Outlook
  • 4.4. Oncology
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. CVD
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million) CVD
  • 4.6. Neurological Diseases or Conditions
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Metabolic Diseases
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.8. Infectious Diseases
    • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. AI-Based Clinical Trials Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Clinical Trial Phase Movement & Market Share Analysis, 2023 & 2030
  • 5.3. Global AI-Based Clinical Trials Solution Providers Market by Clinical Trial Phase Outlook
  • 5.4. Phase-I
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Phase-II
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.6. Phase-III
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. AI-Based Clinical Trials Solution Providers Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. End Use Movement & Market Share Analysis, 2023 & 2030
  • 6.3. Global AI-Based Clinical Trials Solution Providers Market by End Use Outlook
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5. Academia
    • 6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. AI-Based Clinical Trials Solution Providers Market: Regional Estimates & Trend Analysis, By Therapeutic Applications, By Clinical Trial Phase, By End Use

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share/position analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Unlearn.ai, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Technology Type benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Saama
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Technology Type benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Antidote Technologies, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Technology Type benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Phesi
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Technology Type benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Deep6.ai
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Technology Type benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Innoplexus
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Technology Type benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Mendel Health Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Technology Type benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Intelligencia AI
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Technology Type benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Median Technologies
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Technology Type benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. SymphonyAI
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Technology Type benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. BioAge Labs, Inc.
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Technology Type benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. AiCure
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Technology Type benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Consilx
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Technology Type benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. DeepLens.AI
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Technology Type benchmarking
      • 8.4.14.4. Strategic initiatives
    • 8.4.15. HaloHealth
      • 8.4.15.1. Company overview
      • 8.4.15.2. Financial performance
      • 8.4.15.3. Technology Type benchmarking
      • 8.4.15.4. Strategic initiatives
    • 8.4.16. PHARMASEAL
      • 8.4.16.1. Company overview
      • 8.4.16.2. Financial performance
      • 8.4.16.3. Technology Type benchmarking
      • 8.4.16.4. Strategic initiatives
    • 8.4.17. Ardigen
      • 8.4.17.1. Company overview
      • 8.4.17.2. Financial performance
      • 8.4.17.3. Technology Type benchmarking
      • 8.4.17.4. Strategic initiatives
    • 8.4.18. Trials.ai
      • 8.4.18.1. Company overview
      • 8.4.18.2. Financial performance
      • 8.4.18.3. Technology Type benchmarking
      • 8.4.18.4. Strategic initiatives
    • 8.4.19. Koneksa Health
      • 8.4.19.1. Company overview
      • 8.4.19.2. Financial performance
      • 8.4.19.3. Technology Type benchmarking
      • 8.4.19.4. Strategic initiatives
    • 8.4.20. Euretos
      • 8.4.20.1. Company overview
      • 8.4.20.2. Financial performance
      • 8.4.20.3. Technology Type benchmarking
      • 8.4.20.4. Strategic initiatives
    • 8.4.21. BioSymetrics, Inc.
      • 8.4.21.1. Company overview
      • 8.4.21.2. Financial performance
      • 8.4.21.3. Technology Type benchmarking
      • 8.4.21.4. Strategic initiatives
    • 8.4.22. Verily (Google LLC)
      • 8.4.22.1. Company overview
      • 8.4.22.2. Financial performance
      • 8.4.22.3. Technology Type benchmarking
      • 8.4.22.4. Strategic initiatives
    • 8.4.23. Aitia
      • 8.4.23.1. Company overview
      • 8.4.23.2. Financial performance
      • 8.4.23.3. Technology Type benchmarking
      • 8.4.23.4. Strategic initiatives
    • 8.4.24. IBM
      • 8.4.24.1. Company overview
      • 8.4.24.2. Financial performance
      • 8.4.24.3. Technology Type benchmarking
      • 8.4.24.4. Strategic initiatives
    • 8.4.25. Exscientia
      • 8.4.25.1. Company overview
      • 8.4.25.2. Financial performance
      • 8.4.25.3. Technology Type benchmarking
      • 8.4.25.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 4 North America AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 5 North America AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 7 U.S. AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 8 U.S. AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 10 Canada AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 11 Canada AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 14 Europe AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 15 Europe AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Germany AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 17 Germany AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 18 Germany AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 20 UK AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 21 UK AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 23 France AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 24 France AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 26 Italy AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 27 Italy AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 29 Spain AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 30 Spain AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 32 Denmark AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 33 Denmark AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 35 Sweden AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 36 Sweden AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 38 Norway AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 39 Norway AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 44 China AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 45 China AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 46 China AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Japan AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 48 Japan AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 49 Japan AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 51 India AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 52 India AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 53 South Korea AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 54 South Korea AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 55 South Korea AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Australia AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 57 Australia AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 58 Australia AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Thailand AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 60 Thailand AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 61 Thailand AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 64 Latin America AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 65 Latin America AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Brazil AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 67 Brazil AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 68 Brazil AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Argentina AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 70 Argentina AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 71 Argentina AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Mexico AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 73 Mexico AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 74 Mexico AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 75 MEA AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 77 MEA AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 78 MEA AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 79 South Africa AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 80 South Africa AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 81 South Africa AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 86 UAE AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 87 UAE AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
  • Table 89 Kuwait AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
  • Table 90 Kuwait AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 AI-Based Clinical Trials Solution Providers market: market outlook
  • Fig. 9 AI-Based Clinical Trials Solution Providers competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 AI-Based Clinical Trials Solution Providers market driver impact
  • Fig. 15 AI-Based Clinical Trials Solution Providers market restraint impact
  • Fig. 16 AI-Based Clinical Trials Solution Providers market strategic initiatives analysis
  • Fig. 17 AI-Based Clinical Trials Solution Providers market: Therapeutic applications movement analysis
  • Fig. 18 AI-Based Clinical Trials Solution Providers market: Therapeutic applications outlook and key takeaways
  • Fig. 19 Oncology market estimates and forecast, 2018 - 2030
  • Fig. 20 CVD market estimates and forecast, 2018 - 2030
  • Fig. 21 Neurological diseases or conditions market estimates and forecast, 2018 - 2030
  • Fig. 22 Metabolic diseases market estimates and forecast, 2018 - 2030
  • Fig. 23 Infectious diseases market estimates and forecast, 2018 - 2030
  • Fig. 24 Others market estimates and forecast, 2018 - 2030
  • Fig. 25 AI-Based Clinical Trials Solution Providers market: Clinical trial phase analysis
  • Fig. 26 AI-Based Clinical Trials Solution Providers market: Clinical trial phase outlook and key takeaways
  • Fig. 27 Phase-I market estimates and forecast, 2018 - 2030
  • Fig. 28 Phase-II market estimates and forecast, 2018 - 2030
  • Fig. 29 Phase-III market estimates and forecast, 2018 - 2030
  • Fig. 30 AI-Based Clinical Trials Solution Providers market: End use movement analysis
  • Fig. 31 AI-Based Clinical Trials Solution Providers market: End use outlook and key takeaways
  • Fig. 32 Pharmaceutical companies market estimates and forecast, 2018 - 2030
  • Fig. 33 Academia market estimates and forecast, 2018 - 2030
  • Fig. 34 Others market estimates and forecast, 2018 - 2030
  • Fig. 35 Global AI-based clinical trials solution providers market: Regional movement analysis
  • Fig. 36 Global AI-based clinical trials solution providers market: Regional outlook and key takeaways
  • Fig. 37 Global AI-based clinical trials solution providers market share and leading players
  • Fig. 38 North America market share and leading players
  • Fig. 39 Europe market share and leading players
  • Fig. 40 Asia Pacific market share and leading players
  • Fig. 41 Latin America market share and leading players
  • Fig. 42 Middle East & Africa market share and leading players
  • Fig. 43 North America: SWOT
  • Fig. 44 Europe SWOT
  • Fig. 45 Asia Pacific SWOT
  • Fig. 46 Latin America SWOT
  • Fig. 47 MEA SWOT
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030
  • Fig. 53 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 54 France market estimates and forecasts, 2018 - 2030
  • Fig. 55 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 56 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 57 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 61 China market estimates and forecasts, 2018 - 2030
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 63 India market estimates and forecasts, 2018 - 2030
  • Fig. 64 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 65 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 66 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 67 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 68 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 69 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 74 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 76 Company Categorization
  • Fig. 77 Company market position/share analysis
  • Fig. 78 Strategic Framework